人类微生理系统在药物开发中的机遇和挑战
Shekh M Rahman1, Ashok Krishna1, Catherine Sullenberger1
1Division of Applied Regulatory Science (DARS), Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, United States Food and Drug Administration (FDA), Silver Spring, MD, USA.
ALTEX
|January 2, 2025
概括
微生理系统 (MPS) 为药物开发提供先进的体外模型,帮助疾病建模和安全性评估. 标准化和监管机构的接受是最大限度地发挥其在非临床试验中的潜力的关键.
科学领域:
- 生物医学工程 生物医学工程
- 药理学 药理学是指药理学的学科.
- 毒理学 毒理学 毒理学
背景情况:
- 微生理系统 (MPS) 是复杂的体外模型,使用来自各种组织和器官的人类或动物细胞.
- 尽管存在诸如缺乏标准化的局限性,但MPS在药物开发方面表现有前途.
- 进一步的研究和监管接受对于提高MPS有效性至关重要.
研究的目的:
- 审查人类肝脏,肠道,肺部和心脏MPS在药物开发中的应用.
- 专注于疾病建模,安全性评估和药理动力学研究.
- 讨论MPS开发和实施中的技术参数,终点和挑战.
主要方法:
- 关于药物开发中的微生理系统 (MPS) 的当前文献的综述.
- 在疾病建模,安全性和药理动力学方面的应用分析.
- 讨论技术参数,评估终点和挑战.
主要成果:
- 人类肝脏,肠道,肺部和心脏MPS在药物开发中显示出显著的潜力.
- 关键应用包括疾病建模,安全性评估和药理动力学研究.
- 标准化,细胞采购和可复制性等挑战需要解决.
结论:
- 合作努力对于开发MPS标准化协议和验证标准至关重要.
- 预计MPS的进步将提高非临床测试的预测性和可靠性.
- 药物监管部门已经准备好改变药物开发和监管过程.
相关概念视频
Preclinical Development: Overview
4.2K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.2K
Drug Discovery: Overview
7.4K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
7.4K
Pharmacokinetic Models: Comparison and Selection Criterion
38
Physiological and compartmental models are valuable tools used in studying biological systems. These models rely on differential equations to maintain mass balance within the system, ensuring an accurate representation of the dynamic processes at play.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
38
Factors Affecting Drug Response: Overview
1.8K
When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
1.8K
Model Approaches for Pharmacokinetic Data: Physiological Models
28
Physiological models in pharmacokinetics are instrumental in understanding the distribution and elimination of drugs within the body. These models describe the drug concentration within target organs, influenced by factors such as drug uptake, tissue volume, and blood flow. Drug uptake is governed by the partition coefficient, which signifies the drug concentration ratio in tissue to that in the blood. The blood flow rate to a specific tissue is expressed as Qt, and the rate of change in tissue...
28
Physiological Pharmacokinetic Models: Blood Flow-Limited Versus Diffusion-Limited Models
61
Physiological pharmacokinetic models, often called flow-limited or perfusion models, typically assume a swift drug distribution between tissue and venous blood, creating a rapid drug equilibrium. This premise is based on the idea that drug diffusion is extremely fast, and the cell membrane presents no barrier to drug permeation. In this scenario, where no drug binding occurs, the drug concentration in the tissue equals that of the venous blood leaving the tissue. This greatly simplifies the...
61


